Table 2.
Baseline characteristics of participants.
| Clinical Characteristics | N | % |
|---|---|---|
| Age(mean±SD) | 45.9±9.41(26−88) | |
| <40 | 31 | 27.7 |
| ≥40 | 81 | 72.3 |
| Menstruation | ||
| Pre-menopause | 61 | 54.5 |
| Post-menopause | 51 | 45.5 |
| Histological pathology | ||
| No special type | 83 | 74.1 |
| Lobular | 11 | 9.8 |
| Mucious | 4 | 3.6 |
| Tubular | 4 | 3.6 |
| Others | 10 | 8.9 |
| Molecular Characteristic | ||
| ER expression(H-Score) | ||
| 0–10 | 24 | 21.4 |
| 11–199 | 50 | 44.7 |
| ≥200 | 38 | 33.9 |
| PR expression | ||
| <1 % | 26 | 23.2 |
| 1–19 % | 15 | 13.4 |
| ≥20 % | 71 | 63.4 |
| HER2 (Immunohistochemistry) | ||
| 0/1+ | 57 | 50.9 |
| 2+ | 29 | 25.9 |
| 3+ | 26 | 23.2 |
| Molecular subtypes | ||
| Luminal A | 16 | 14.3 |
| Luminal B, HER2- | 59 | 52.7 |
| Luminal B, HER2+ | 14 | 12.5 |
| HER2 | 12 | 10.7 |
| Triple negative | 11 | 9.8 |